Prot #GSN000350: TRANSFORM: A 52-week, Randomized, Placebo-controlled, Double-blind, Adaptive Phase 2b/3 Trial of Setanaxib with a 52-week Extension Phase in Patients with Primary Biliary Cholangitis (PBC) and Elevated Liver Stiffness

Project: Research project

Project Details

StatusActive
Effective start/end date2/14/222/14/25

Funding

  • Pharmaceutical Research Associates, Inc. (Prot #GSN000350)
  • GenKyoTex Suisse SA (Prot #GSN000350)